Repeated NT-proBNP testing and risk for adverse outcome after acute pulmonary embolism

Wendy Zondag; Mariette J. Agterof; Roger E. G. Schutgens; Olaf M. Dekkers; Douwe H. Biesma; Menno V. Huisman

doi:10.1160/TH11-07-0462

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(06): 1226-1227
DOI: 10.1160/TH11-07-0462

Letters to the Editor

Schattauer GmbH

Repeated NT-proBNP testing and risk for adverse outcome after acute pulmonary embolism

Wendy Zondag^*

¹Section of Vascular Medicine, Department of Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands

,

Mariette J. Agterof^*

²Van Creveldkliniek/Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands

,

Roger E. G. Schutgens

²Van Creveldkliniek/Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands

,

Olaf M. Dekkers

³Department of Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands

,

Douwe H. Biesma

²Van Creveldkliniek/Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands

⁴St. Antonius Hospital, Nieuwegein, The Netherlands

,

Menno V. Huisman

¹Section of Vascular Medicine, Department of Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands

› Author Affiliations

Abstract

Full Text

References

References
1 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425-430.
2 ten Wolde M, Tulevski I I, Mulder JW. et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084.
3 Kucher N, Printzen G, Doernhoefer et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578.
4 Kostrubiec M, Pruszczyk P, Bochowicz A. et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-2172.
5 Vuilleumier N, Perrier A, Sanchez JC. et al. Cardiac biomarkers levels predict pulmonary embolism extent on chest computed tomography and prognosis in non-massive pulmonary embolism. Thromb Haemost 2009; 101: 1176-1178.
6 Becattini C, Agnelli G. Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb Haemost 2008; 100: 747-751.
7 Agterof MJ, Schutgens RE, Snijder RJ. et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010; 8: 1235-1241.
8 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
9 Kostrubiec M, Pruszczyk P, Kaczynska A. et al. Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. Clin Chim Acta 2007; 382: 124-128.